PCM
SPRY icon

Peregrine Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

Peregrine Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.38M Buy
+672,139
New +$5.78M 0.17% 183
2025
Q3 		– Sell
-456,979
Closed -$7.97M – 351
2025
Q2 		$7.97M Sell
456,979
-44,842
-9% -$647K 0.24% 117
2025
Q1 		$6.31M Buy
501,821
+78,260
+18% +$942K 0.21% 139
2024
Q4 		$4.47M Buy
+423,561
New +$5.93M 0.13% 231

Other funds holding SPRY

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
NFGCM
Norman Fields Gottscho Capital Management New York $330M AUM 27.75% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
CI
CX Institutional Auburn, Indiana $3.46B AUM 21.89% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Peregrine Capital Management's SPRY Position: Q2 2026 in Review

Peregrine Capital Management opened a new position in ARS Pharmaceuticals (SPRY) in Q2 2026: 672,139 shares worth $5.38M. The stake represents 0.17% of the portfolio and ranks #183 among its holdings. This is a return to the name: Peregrine Capital Management previously reported a position in SPRY as recently as Q2 2025.

Peregrine Capital Management first reported a position in SPRY in Q4 2024 and has held it in 4 quarters since. The position peaked at $7.97M in Q2 2025. 8 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Peregrine Capital Management held 672,139 shares of ARS Pharmaceuticals worth $5.38M as of Q2 2026.
  • ARS Pharmaceuticals was a new Peregrine Capital Management position in Q2 2026.
  • ARS Pharmaceuticals made up 0.17% of Peregrine Capital Management's portfolio in Q2 2026, its #183 holding.
  • Peregrine Capital Management first reported a position in ARS Pharmaceuticals in Q4 2024 and has held it in 4 quarters since.
  • Peregrine Capital Management's ARS Pharmaceuticals position peaked at $7.97M in Q2 2025.
  • 8 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Peregrine Capital Management's 13F filing for Q2 2026, filed 17 Jul 2026.